Calidi Biotherapeutics Stock Performance
| CLDI Stock | 1.02 0.03 2.86% |
The firm shows a Beta (market volatility) of 0.48, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Calidi Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Calidi Biotherapeutics is expected to be smaller as well. At this point, Calidi Biotherapeutics has a negative expected return of -0.59%. Please make sure to confirm Calidi Biotherapeutics' treynor ratio, accumulation distribution, period momentum indicator, as well as the relationship between the potential upside and day median price , to decide if Calidi Biotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Calidi Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in March 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor 1:12 | Last Split Date 2025-08-05 |
1 | Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC | 11/10/2025 |
2 | Calidi Biotherapeutics GAAP EPS of -2.21 misses by 0.53 | 11/13/2025 |
3 | What margin trends mean for Calidi Biotherapeutics Inc. stock - Quarterly Trade Report Expert Approved Momentum Ideas - newser.com | 11/18/2025 |
4 | Will Calidi Biotherapeutics Inc. stock outperform international peers - July 2025 Chart Watch Accurate Intraday Trade Tips - B NI V | 11/28/2025 |
5 | Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - Greenville Online | 12/05/2025 |
6 | Disposition of 850 shares by Allan Camaisa of Calidi Biotherapeutics at 1.455 subject to Rule 16b-3 | 12/12/2025 |
7 | How risky is Calidi Biotherapeutics Inc. stock now - Dollar Strength Real-Time Sentiment Analysis - | 12/18/2025 |
8 | Will Calidi Biotherapeutics Inc. stock outperform international peers - Dividend Stock Watch Download Our Free Trading Blueprint - bollywoodhelpline.com | 12/26/2025 |
9 | How sustainable is Calidi Biotherapeutics Inc. stock dividend payout - Profit Target Daily Momentum Trading Reports - ulpravda.ru | 01/08/2026 |
10 | Calidi Biotherapeutics Sets 2026 Priorities After 2025 Progress - TipRanks | 01/29/2026 |
| Begin Period Cash Flow | 2.2 M | |
| Total Cashflows From Investing Activities | -16 K |
Calidi Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 153.00 in Calidi Biotherapeutics on November 2, 2025 and sell it today you would lose (51.00) from holding Calidi Biotherapeutics or give up 33.33% of portfolio value over 90 days. Calidi Biotherapeutics is currently does not generate positive expected returns and assumes 3.8297% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Calidi, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Calidi Biotherapeutics Target Price Odds to finish over Current Price
The tendency of Calidi Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.02 | 90 days | 1.02 | under 95 |
Based on a normal probability distribution, the odds of Calidi Biotherapeutics to move above the current price in 90 days from now is under 95 (This Calidi Biotherapeutics probability density function shows the probability of Calidi Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Calidi Biotherapeutics has a beta of 0.48 suggesting as returns on the market go up, Calidi Biotherapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Calidi Biotherapeutics will be expected to be much smaller as well. Additionally Calidi Biotherapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Calidi Biotherapeutics Price Density |
| Price |
Predictive Modules for Calidi Biotherapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Calidi Biotherapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Calidi Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Calidi Biotherapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Calidi Biotherapeutics is not an exception. The market had few large corrections towards the Calidi Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Calidi Biotherapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Calidi Biotherapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.54 | |
β | Beta against Dow Jones | 0.48 | |
σ | Overall volatility | 0.19 | |
Ir | Information ratio | -0.15 |
Calidi Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Calidi Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Calidi Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Calidi Biotherapeutics generated a negative expected return over the last 90 days | |
| Calidi Biotherapeutics has some characteristics of a very speculative penny stock | |
| Calidi Biotherapeutics has high historical volatility and very poor performance | |
| Calidi Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K. | |
| Calidi Biotherapeutics generates negative cash flow from operations | |
| Calidi Biotherapeutics has a poor financial position based on the latest SEC disclosures | |
| About 15.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Calidi Biotherapeutics Sets 2026 Priorities After 2025 Progress - TipRanks |
Calidi Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Calidi Stock often depends not only on the future outlook of the current and potential Calidi Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Calidi Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 664.4 K | |
| Cash And Short Term Investments | 9.6 M |
Calidi Biotherapeutics Fundamentals Growth
Calidi Stock prices reflect investors' perceptions of the future prospects and financial health of Calidi Biotherapeutics, and Calidi Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Calidi Stock performance.
| Return On Asset | -1.2 | ||||
| Current Valuation | 459.11 K | ||||
| Shares Outstanding | 7.17 M | ||||
| Price To Book | 1.09 X | ||||
| Price To Sales | 50.83 X | ||||
| Gross Profit | 31 K | ||||
| EBITDA | (19.73 M) | ||||
| Net Income | (22.21 M) | ||||
| Total Debt | 7.04 M | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | (19.69 M) | ||||
| Earnings Per Share | 0.36 X | ||||
| Market Capitalization | 7.53 M | ||||
| Total Asset | 14.18 M | ||||
| Retained Earnings | (121.72 M) | ||||
| Working Capital | 731 K | ||||
About Calidi Biotherapeutics Performance
By evaluating Calidi Biotherapeutics' fundamental ratios, stakeholders can gain valuable insights into Calidi Biotherapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Calidi Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Calidi Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.41) | (1.48) | |
| Return On Capital Employed | (4.18) | (3.97) | |
| Return On Assets | (1.41) | (1.48) | |
| Return On Equity | (16.60) | (15.77) |
Things to note about Calidi Biotherapeutics performance evaluation
Checking the ongoing alerts about Calidi Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Calidi Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Calidi Biotherapeutics generated a negative expected return over the last 90 days | |
| Calidi Biotherapeutics has some characteristics of a very speculative penny stock | |
| Calidi Biotherapeutics has high historical volatility and very poor performance | |
| Calidi Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K. | |
| Calidi Biotherapeutics generates negative cash flow from operations | |
| Calidi Biotherapeutics has a poor financial position based on the latest SEC disclosures | |
| About 15.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Calidi Biotherapeutics Sets 2026 Priorities After 2025 Progress - TipRanks |
- Analyzing Calidi Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Calidi Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Calidi Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Calidi Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Calidi Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Calidi Biotherapeutics' stock. These opinions can provide insight into Calidi Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Calidi Stock analysis
When running Calidi Biotherapeutics' price analysis, check to measure Calidi Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calidi Biotherapeutics is operating at the current time. Most of Calidi Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Calidi Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calidi Biotherapeutics' price. Additionally, you may evaluate how the addition of Calidi Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |